Blood marker may forecast deadly pancreatic surgery complications
NCT ID NCT07144917
First seen Apr 16, 2026 · Last updated Jun 09, 2026 · Updated 10 times
Summary
This study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC FISTULA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aurélien DUPRE
NOT_YET_RECRUITINGLyon, 69008, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jean-Christophe LIFANTE
NOT_YET_RECRUITINGPierre-Bénite, 69495, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Julie PERINEL
NOT_YET_RECRUITINGLyon, 69003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xavier MULLER
RECRUITINGLyon, 69004, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.